Company intelligence / Profile preview

CardioMech

Ownership: Private
Development stage: Preclinical

Overview

CardioMech has developed a catheter-based artificial chord device for minimally invasive treatment of degenerative mitral regurgitation. The company completed its first-in-human procedure in 2021 and plans to begin an FDA early feasibility study in the US. The technology aims to reduce or eliminate regurgitation by restoring native anatomy without open-heart surgery. Clinical results are investigational and not yet published as pivotal data.

Therapeutic areas: CardiovascularRare Diseases
Modalities: Device (specifically, artificial chord for mitral valve repair)
Industry: Implantable Medical Devices

Partnerships

Not publicly disclosed; includes non-disclosed strategic investor(s)

Beyond the preview

Go deeper on CardioMech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CardioMech.

Explore the full profile